KV Pharma, ex-chief wrestle over roots of 2008 crisis

How to explain KV Pharmaceuticals' sudden skid in 2008? The company has one version, and ex-CEO Mark Hermelin has another--and that's the gist of the ongoing court fight. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.